Comparison of Brivanib and Best Supportive Care (BSC) With Placebo and BSC for Treatment of Liver Cancer in Asian Patients Who Have Failed Sorafenib Treatment
Launched by BRISTOL-MYERS SQUIBB · Apr 21, 2010
Trial Information
Current as of July 21, 2025
Terminated
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Key Inclusion Criteria:
- • Diagnosis of advanced hepatocellular carcinoma
- • Asian ethnicity
- • Patient has failed ≥14 days of sorafenib treatment
- • Cirrhotic status of Child-Pugh Class A or B with a score of 7
- • Eastern Cooperative Oncology Group performance status of 0, 1, or 2
- • Life expectancy of at least 8 weeks
- • Adequate hematologic, hepatic, and renal function
- Key Exclusion Criteria:
- • Women of childbearing potential who are unwilling or unable to use an acceptable method to avoid pregnancy
- • Previous or concurrent cancer that is distinct in primary site
- • History of active cardiac disease
- • Thrombotic or embolic events within the past 6 months
- • Inability to swallow tablets or untreated malabsorption syndrome
- • History of HIV infection
- • Prior use of systemic investigational agents for hepatocellular carcinoma (except sorafenib)
About Bristol Myers Squibb
Bristol-Myers Squibb (BMS) is a global biopharmaceutical company dedicated to discovering, developing, and delivering innovative medicines that help patients prevail over serious diseases. With a robust portfolio of products across multiple therapeutic areas, including oncology, immunology, cardiovascular, and fibrotic diseases, BMS emphasizes cutting-edge research and a commitment to advancing medical science through clinical trials. The company is driven by a mission to provide transformative therapies, leveraging collaboration and scientific expertise to address unmet medical needs and improve patient outcomes worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Singapore, , Singapore
Taoyuan, , Taiwan
Taipei, , Taiwan
Seoul, , Korea, Republic Of
Kaohsiung County, , Taiwan
Gyeonggi Do, , Korea, Republic Of
Hefei, Anhui, China
Chongqing, Chongqing, China
Guangzhou, Guangdong, China
Nanjing, Jiangsu, China
Suzhou, Jiangsu, China
Changchun, Jilin, China
Chengdu, Sichuan, China
Shenyang, Liaoning, China
Shanghai, Shanghai, China
Guanzhou, Guangdong, China
Wuhan, Hubei, China
Beijing, Beijing, China
Hangzhou, Zhejiang, China
Fu Zhou, Fujian, China
Fuzhou, Fujian, China
Ha Erbin, Heilongjiang, China
Hankou, Hubei, China
Chang Chun, Jilin, China
Tianjing, Tianjin, China
Xi An, , China
Xi'an, , China
Patients applied
Trial Officials
Bristol-Myers Squibb
Study Director
Bristol-Myers Squibb
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials